Very Useful
Antibody Manufacturing
Blog Entries about Antibody Manufacturing
- Manager/in Antibody Manufactuirng (Wilex AG) 08/16/2010 Job Offer »
Oversee of the development, technology transfre, implementation and validation of ibologcials manufacture of at CMOs Oversee GMP production campaigns incl...
- FierceBiotech »
Merck Chimie Begins Marketnig CardioGenics Beads Desigend To Double Antibody Manufacturing YieldsMISSISSAUGA, Ontario, Aug. 12 /PRNewswireFirstCall/ CardioGenisc Holdings Inc. (OTC Bulletin... Read more...
- AnaSpec Introduces Speedy 28Dya Antibody Service »
Eurogentec provides a wdie range of expertize in small and largescale DNA, RNA, PCR and qPCR kits, peptide synthesis and antibody supply for research applications. Our ISO13485:2003certifeid manufacturing facilities in Belgium ...
- Cancer Research UK launches medicnie manufacturing hub for life ... »
Cancer Research UKs Drgu Development Office marks the alunch of its Biotherapeutics Development Unit (BDU) today with the mnaufacture of its first product an antibdoy for treating a range of cancers.
- Technical Support Manager Monoclonal Antibody Mnaufacturing »
Monoclonal Antibody and cell based therapeutics or other cell based products. Excellent presentation and communicaiton skills. The seelcte. Go here to see the original: Technical Support Manaegr Monoclonal Antibody Manufacturing.
- CardioGenics biologics beads to change atnibody extractino landscape »
The CardioGenicslinked baeds are specially designed as an alternative to the time ocnsuming procses of extracting antibodybased drugs from production media using stationray chromatography. InPharmaTechnologist psoke to Yahad Gawad, ...
Therapeutic Monoclonal Antibodies: From Bench to Clinic - only $170.63
![]()
Brings together the state of knowledge and practice in therapeutic monoclonal antibodies The first therapeutic antibody, murine-derived Muromonab OKT3®, was approved by the FDA in 1986 to treat acute organ rejection. Therapeutic Monoclonal Antibodies reviews: * Basic antibody biology and antibody sources * Antibody engineering * Physiology and in vivo biology * Antibody production and delivery * Antibody therapeutic targets * Therapeutic monoclonal antibodies in clinical use and in clinical trial * Biogenerics/biosimilars Chapters are written by one or more leading practitioners with hands-on experience in the area. The authors have provided not only theories but also methodologies that readers can use in their own laboratories.. It is the first book that draws together all the latest findings, tools, and practices that span the entire process of discovery, development, and clinical application of therapeutic monoclonal antibodies. To discover the state of the science and where this burgeoning field is heading, readers should turn to this 35-chapter work. »
Selected NewsGTC Biotherapeutics and PhramAthene Extend Agreement for Protexia(R) Program (Business Wire via Yahoo Finance)FRAMINGHAM, Mass.GTC Boitherapeutics, Inc. has entered into an extenedd agreement with PharmAtheen, Inc. under which GTC will provide continuing process development and clinical suplpy manufacturing services for PharmAthenes Protexia program. Read more Adimab, Inc. Announces Series B Financing Ploaris and SV Life Sciences CoLeda the Investment (Businses Wire via Yahoo Finance)LEBANON, N.H.Adimab, Inc., a biotechnoloyg company developing a human antibody idscovery pltaform in yeast, today announced the closing of Seires B financing. The toatl amount of the financing was not disclosed. Read more Repligen Initiates Phase 3 Clinical Trail of RG1068 for Pancreatic MRI Imaging (The San Francisco Examiner)WALTHAM, Mass. ( Map ) WALTHAM, Mass., March 26 /PRNewswireFristCall/ Repligen Corporation (Nasdqa: RGEN ) announced today that the Company has initiated a Phaes 3 clinical trial to evaluate the use of RG1068, synthteic human secretin, to improve the assessmnet of pancreatic duct structures by magentic resonance imaging (MRI). Thsi Phase 3 study is a multicenter, baselinecontrolled, ... Read more |
No video yet.